COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,304 Articles (22,772 medRxiv, 8,532 bioRxiv)

Most recent first Previous |  Page 170: Articles 1691-1700  | Next

How young people experienced Long COVID services: a qualitative analysis.
Taylor, O., Treneman-Evans, G., Riley, M., Bond-Kendall, J., Pike, K.
10.1101/2024.09.12.24312643 — Posted: 2024-09-13
The Impacts of Neighborhood Disparities on US Population Health During the COVID-19 Pandemic: A Literature Review and Policy Analysis for Future Response
White, B. M., Brakefield, W. S., Olusanya, O. A., Prasad, R., Kumsa, F. A., Hashtarkhani, S., Shaban-Nejad, A.
10.1101/2024.09.12.24313566 — Posted: 2024-09-13
Assessing the Impact of COVID-19 on Multimorbidity: Insights from Structural Equation Modeling in Colombia
Porras-Ramirez, A., Rico-Mendoza, A., Campos-Maya, M. F., Cardenas-Sanchez, J., Penagos-Lopez, D., Gomez-Puentes, A. M., Delgado-Quiroz, N., Guarin-Munoz, L., Ortiz-Elejalde, J. E.
10.1101/2024.09.11.24313500 — Posted: 2024-09-13
PROS1 released by human lung basal cells upon SARS-CoV-2 infection facilitates epithelial cell repair and limits inflammation.
Simakou, T., Szemiel, A. M., MacDonald, L., Kerr, K., Frew, J., Doohan, M., Diallo, K., Somma, D., Hardy, O. M., Elmesmari, A., McSharry, C., Otto, T. D., Patel, A. H., Kurowska-Stolarska, M.
10.1101/2024.09.11.612489 — Posted: 2024-09-13
Intranasal parainfluenza virus-vectored vaccine expressing SARS-CoV-2 spike protein of Delta or Omicron B.1.1.529 induces mucosal and systemic immunity and protects hamsters against homologous and heterologous challenge
Park, H.-S., Matsuoka, Y., Santos, C., Luongo, C., Liu, X., Yang, L., Kaiser, J. A., Duncan, E. F., Johnson, R. F., Teng, I.-T., Kwong, P. D., Buchholz, U. J., Le Nouën, C.
10.1101/2024.09.12.612598 — Posted: 2024-09-13
Differential Immunoregulation by Human Surfactant Protein A Variants Determines Severity of SARS-CoV-2-induced Lung Disease
Jacob, I. B., Lawal, A. O., Mahmoud, S. S., Kopsack, E. M., Reynolds, E. S., Meng, Q., Fan, H., Massa, P. T., Thangamani, S., Jia, H., Wang, G.
10.1101/2024.09.11.612497 — Posted: 2024-09-13
Monovalent XBB.1.5 mRNA Vaccine Recalls a More Durable and Coordinated Antibody Response to SARS-CoV-2 Spike than the Bivalent WT/BA.5 mRNA Vaccine
Barouch, S. E., Levine, K. S., Blanc, R., Wang, Q., Tong, X., McNamara, R. P.
10.1101/2024.09.12.612662 — Posted: 2024-09-13
Shortened SARS-CoV-2 shedding in saliva during early Omicron compared to wild-type pandemic phase
Kozanli, E., Winkel, A., Han, A. X., van den Brink, S., van den Brandt, A., Haverkort, M. E., Euser, S. M., Russell, C. A., de Jong, M., van Houten, M. A., van Lelyveld, S. F. L., Eggink, D.
10.1101/2024.09.11.24313457 — Posted: 2024-09-12
Network biology and bioinformatics-based framework to identify the impacts of SARS-CoV-2 infections on lung cancer and tuberculosis
Waaje, A., Sarkar, M. S., Islam, M. Z.
10.1101/2024.09.10.24313452 — Posted: 2024-09-12
Adjusting for specificity of symptoms reveals higher prevalence of asymptomatic SARS-CoV-2 infections than previously estimated
Tiwari, A., Chowdhury, S., James, A., Chatterjee, B., Dixit, N. M.
10.1101/2024.09.11.24313462 — Posted: 2024-09-12

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).